Get the Stockscreener App
3.68
6.96%
-0.27
Alto Neuroscience Inc stock is traded at $3.68, with a volume of 181.60K.
It is down -6.96% in the last 24 hours and down -18.69% over the past month.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
See More
Previous Close:
$3.95
Open:
$3.96
24h Volume:
181.60K
Relative Volume:
0.57
Market Cap:
$100.60M
Revenue:
-
Net Income/Loss:
$-49.81M
P/E Ratio:
-1.7069
EPS:
-2.156
Net Cash Flow:
$-42.93M
1W Performance:
-14.34%
1M Performance:
-18.69%
6M Performance:
-58.57%
1Y Performance:
-80.64%
1-Day Range:
$3.665
$4.03
1-Week Range:
$3.665
$4.30
52-Week Range:
$3.56
$19.66
Alto Neuroscience Inc Stock (ANRO) Company Profile
Name
Alto Neuroscience Inc
Sector
Industry
Phone
773-255-5012
Address
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Compare ANRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
3.6795 | 100.60M | 0 | -49.81M | -42.93M | -2.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.10 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
714.65 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
647.58 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.02 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.34 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-23-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Oct-23-24 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-03-24 | Initiated | Wedbush | Outperform |
| Feb-27-24 | Initiated | Jefferies | Buy |
| Feb-27-24 | Initiated | Robert W. Baird | Outperform |
| Feb-27-24 | Initiated | Stifel | Buy |
| Feb-27-24 | Initiated | TD Cowen | Outperform |
| Feb-27-24 | Initiated | William Blair | Outperform |
View All
Alto Neuroscience Inc Stock (ANRO) Latest News
Schizophrenia Drugs Market reached US$ 10.03 billion in 2024 - openPR
Alto Neuroscience, Inc. (NYSE:ANRO) Receives $20.00 Average Price Target from Analysts - MarketBeat
Alto Neuroscience announces $75 million ATM offering - MSN
Alto Neuroscience Files For Mixed Shelf Of Up To $300 Million -February 03, 2025 at 05:06 pm EST - Marketscreener.com
Alto Neuroscience announces $75 million ATM offering By Investing.com - Investing.com UK
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Precision neuropsychiatry spotlight: a BioCentury podcast - BioCentury
JPMorgan Chase & Co. Acquires 20,536 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alto Neuroscience, Inc. (ANRO) And Encourages Stockholders to Reach Out - ACCESS Newswire
Barclays PLC Raises Stock Position in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Jane Street Group LLC Takes $124,000 Position in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
All You Need to Know About Alto Neuroscience, Inc. (ANRO) Rating Upgrade to Buy - Yahoo Finance
Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Stock Holdings Increased by Geode Capital Management LLC - Defense World
Alto Neuroscience, Inc. (NYSE:ANRO) Shares Bought by Geode Capital Management LLC - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Shares Acquired by Barclays PLC - Defense World
State Street Corp Grows Position in Alto Neuroscience, Inc. (NYSE:ANRO) - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Shares Purchased by State Street Corp - Defense World
Alto Neuroscience Presents Key Data, Study Findings on ALTO-300 - Psychiatric Times
For precision psychiatry, 2024 was one step forward, two steps back - BioWorld Online
Franklin Resources Inc. Buys 595,673 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Position Boosted by BNP Paribas Financial Markets - Defense World
Charles Schwab Investment Management Inc. Acquires 120,779 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Jones Trading sets Alto Neuroscience shares at Buy on portfolio By Investing.com - Investing.com Canada
This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Alto Neuroscience, Inc. (NYSE:ANRO) Sees Significant Drop in Short Interest - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Shares Bought by The Manufacturers Life Insurance Company - Defense World
Alto Neuroscience, Inc. (NYSE:ANRO) Receives $20.00 Average PT from Analysts - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology - BioSpace
Alto Neuroscience Unveils Breakthrough Precision Psychiatry Data at Major Neuroscience Conference - StockTitan
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm - The Eastern Progress Online
ANRO Investors Have Opportunity to Join Alto Neuroscience, Inc. Fraud Investigation with the Schall Law Firm - The Eastern Progress Online
Fmr LLC Boosts Stake in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Jennison Associates LLC Buys 370,612 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - MarketBeat
Alto Neuroscience (NYSE:ANRO) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
What is William Blair's Forecast for ANRO FY2024 Earnings? - MarketBeat
Wedbush Equities Analysts Reduce Earnings Estimates for ANRO - MarketBeat
RA Capital Management Reduces Stake in Alto Neuroscience Inc - GuruFocus.com
Stifel Nicolaus Has Lowered Expectations for Alto Neuroscience (NYSE:ANRO) Stock Price - MarketBeat
FMR LLC Acquires Shares in Alto Neuroscience Inc - GuruFocus.com
Alto Neuroscience Reports $182M Cash Position Despite Widening Losses in Q3 | ANRO Stock News - StockTitan
Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Yahoo Finance
Latest Company News - Investing.com
Largest borrow rate increases among liquid names - TipRanks
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC - GlobeNewswire
Alto Neuroscience to Participate in Upcoming Investor Conferences - StockTitan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Alto Neuroscience, Inc. (ANRO) And Encourages Stockholders to Connect - AccessWire
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Alto Neuroscience Inc Stock (ANRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):